

Ascelia Pharma Gets Acceptance for Publication of Orviglance Review Article in Investigative Radiology

Ascelia Pharma AB (publ) (ticker: ACE), a biotech company focused on improving the life of people living with rare cancer conditions, today announced the acceptance for publication of a scientific review article on its orphan drug candidate Orviglance® in the journal *Investigative Radiology* in a special issue "A new era in MR contrast media". The publication will be available online in the first quarter of 2024.

The scientific review article, titled *Oral manganese chloride tetrahydrate, a novel magnetic resonance liver imaging agent for patients with renal impairment: efficacy, safety and clinical implication*, reviews and discusses liver imaging in patients with severely impaired kidney function as well as the development of Orviglance and its potential role in clinical practice. The review article will be published in *Investigative Radiology* in a special issue "A new era in MR contrast media", which will be available online in the first quarter of 2024.

"It's a pleasure to have this publication accepted in one of the leading journals in radiology, which shows that the scientific community sees a need for novel contrast agents without gadolinium. This strengthens our confidence in the unmet need for patients and clinicians as we approach headline data from our Phase 3 study and progress Orviglance towards regulatory approval." said Andreas Norlin, CSO of Ascelia Pharma.

Ascelia Pharma is thankful to the authors including Torkel B Brismar, MD PhD, Professor (Karolinska Institutet, Stockholm), Dominik Geisel, MD, Professor (Charité Universitätsmedizin Berlin), Nikolaos Kartalis PhD, Associate Professor (Karolinska University, Stockholm), and Beatrice L. Madrazo (University of Miami/Miller School of Medicine, Miami, Florida).

Orviglance has been granted an Orphan Drug Designation by the US Food and Drug Administration (FDA) for liver imaging in patients with severely impaired kidney function. With Orviglance, these patients can gain access to effective liver imaging without gadolinium-related safety risks. The unmet need for these patients represents an addressable market potential of USD 800 million globally; almost half of which is in the US.

Headline results from the Phase 3 clinical study, SPARKLE, with Orviglance are expected by May 2024.

Contacts - Magnus & Julie

Magnus Corfitzen, CEO
Email: moc@ascelia.com
Tel: +46 735 179 118

Julie Waras Brogren, Deputy CEO (Finance, Investor Relations & Commercial)
Email: jwb@ascelia.com
Tel: +46 735 179 116

This information was submitted for publication, through the agency of the contact persons set out above.

About us

About Ascelia Pharma

Ascelia Pharma is a biotech company focused on orphan oncology treatments. We develop and commercialize novel drugs that address unmet medical needs and have a clear development and market pathway. The company has two drug candidates – Orviglance® (Mangoral) and Oncoral – in clinical development. Ascelia Pharma has its global headquarters in Malmö, Sweden, and is listed on Nasdaq Stockholm (ticker: ACE). For more information, please visit www.ascelia.com.

About Orviglance

Orviglance (manganese chloride tetrahydrate) is a novel oral contrast agent for magnetic resonance imaging (MRI) developed to improve the detection and visualization of focal liver lesions (including liver metastases and primary tumors) in patients with reduced kidney function. These patients are at risk of serious side effects from the currently available class of gadolinium-based contrast agents. Orviglance, has been granted an Orphan Drug Designation by the US Food and Drug Administration (FDA). A clinical program of nine studies, including the pivotal global Phase 3 study SPARKLE, has been completed. Results from the Phase 3 study are not yet available.

Attachments

[Ascelia Pharma Gets Acceptance for Publication of Orviglance Review Article in Investigative Radiology](#)